BPC-157 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-25 and is reviewed periodically as new material appears.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection of dry material |
| Solubility | Soluble in water | Polar aqueous solvent class |
| Typical storage | Minus 20 degrees Celsius, desiccated, dark | Applies to the lyophilized form |
| Purity assessment | Reversed-phase HPLC | Ultraviolet detection, area percent |
| Identity confirmation | Mass spectrometry | Measured mass compared with theoretical value |
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
=== Primary or secondary === The distinction between primary and secondary immunodeficiencies is based on whether the cause originates in the immune system itself or insufficiency of a supporting component or an external factor.
The documentary Beetles, Record Breakers makes use of 15 different terms to refer to beetles in less than 30 minutes (longhorn beetle, cellar beetle, stag beetle, burying beetle or gravediggers, sexton beetle, tiger beetle, bloody nose beetle, tortoise beetle, diving beetle, devil's coach horse, weevil, click beetle, malachite beetle, oil beetle, cockchafer), apart from mentioning other animals such as horseshoe bats or meadow brown butterflies.
Glucose is mainly used for the production of fructose and of glucose-containing foods. In foods, it is used as a sweetener, humectant, to increase the volume and to create a softer mouthfeel. Various sources of glucose, such as grape juice (for wine) or malt (for beer), are used for fermentation to ethanol during the production of alcoholic beverages. Most soft drinks in the US use HFCS-55 (with a fructose content of 55% in the dry mass), while most other HFCS-sweetened foods in the US use HFCS-42 (with a fructose content of 42% in the dry mass). In Mexico, on the other hand, soft drinks are sweetened by cane sugar, which has a higher sweetening power. In addition, glucose syrup is used, among other things, in the production of confectionery such as candies, toffee, and fondant. Typical chemical reactions of glucose when heated under water-free conditions are caramelization and, in presence of amino acids, the Maillard reaction.
== History == Reslizumab was initially developed by Chuan-Chu Chou at Schering-Plough and was previously known as SCH-55700. In 1993, Chou and his group at Schering-Plough were granted the patent for the design, cloning and expression of the reslizumab drug. Ception Therapeutics acquired the drug and continued its development under the name CTx55700. In 2010, Ception Therapeutics was acquired by Cephalon for $250 million and the drug continued under development under the codename CEP-38072. In 2011, Teva Pharmaceuticals acquired Cephalon for $6.8 billion and continued the development of reslizumab.
On 21 December 2020, President of the United States Donald Trump awarded Modi with the Legion of Merit for elevating India–United States relations. The Legion of Merit was awarded to Modi along with Prime Minister of Australia Scott Morrison and former Prime Minister of Japan Shinzo Abe, the "original architects" of the QUAD.
Sources: en.wikipedia.org
Neurolathyrism, is a neurological disease of humans, caused by eating certain legumes of the genus Lathyrus. This disease is mainly associated with the consumption of Lathyrus sativus (also known as grass pea, chickling pea, kesari dal, or almorta) and to a lesser degree with Lathyrus cicera, Lathyrus ochrus and Lathyrus clymenum containing the toxin ODAP. This is not to be confused with osteolathyrism, a different type of lathyrism that affects the connective tissues. Osteolathyrism results from the ingestion of Lathyrus odoratus seeds (sweet peas) and is often referred to as odoratism. It is caused by a different toxin (beta-aminopropionitrile) which affects the linking of collagen, a protein of connective tissues. Another type of lathyrism is angiolathyrism which is similar to osteolathyrism in its effects on connective tissue. However, the blood vessels are affected as opposed to bone.
=== Economics === The number of e-cigarettes sold increased every year from 2003 to 2014. As of 2014, there were at least 466 e-cigarette brands. Worldwide e-cigarette sales in 2014 were around US$7 billion. Worldwide e-cigarette sales in 2019 were about $19.3 billion. In 2021, the global e-cigarette market was estimated at about US$20.4 billion. In the United States, Reuters reported (citing Circana retail tracking reviewed by Reuters) that illegal sales of flavored disposable vapes reached about $2.4 billion in 2024 and accounted for roughly 35% of all e-cigarette sales in mainstream retail outlets tracked by Circana; Circana estimated the total tracked vape market at $6.8 billion, excluding online and specialty store sales. E-cigarette sales could exceed traditional cigarette sales by 2023.
This was partly because Paleolithic hunter-gatherers accessed a wider variety of natural foods, which allowed them a more nutritious diet and a decreased risk of famine. Many of the famines experienced by Neolithic (and some modern) farmers were caused or amplified by their dependence on a small number of crops. It is thought that wild foods can have a significantly different nutritional profile than cultivated foods. The greater amount of meat obtained by hunting big game animals in Paleolithic diets than Neolithic diets may have also allowed Paleolithic hunter-gatherers to enjoy a more nutritious diet than Neolithic agriculturalists. It has been argued that the shift from hunting and gathering to agriculture resulted in an increasing focus on a limited variety of foods, with meat likely taking a back seat to plants. It is also unlikely that Paleolithic hunter-gatherers were affected by modern diseases of affluence such as type 2 diabetes, coronary heart disease, and cerebrovascular disease, because they ate mostly lean meats and plants and frequently engaged in intense physical activity, and because the average lifespan was shorter than the age of common onset of these conditions. Large-seeded legumes were part of the human diet long before the Neolithic Revolution, as evident from archaeobotanical finds from the Mousterian layers of Kebara Cave, in Israel. There is evidence suggesting that Paleolithic societies were gathering wild cereals for food use at least as early as 30,000 years ago.
The sexism was evident in many ways, according to Mamphela Ramphele, a BCM activist and doctor at the Zanempilo Clinic, including that women tended to be given responsibility for the cleaning and catering at functions. "There was no way you could think of Steve making a cup of tea or whatever for himself", another activist said. Feminism was viewed as irrelevant "bra-burning". Surrounded by women who cared about him, Biko developed a reputation as a womaniser, something that Woods described as "well earned". He displayed no racial prejudice, sleeping with both black and white women. At NUSAS, he and his friends competed to see who could have sex with the most female delegates. Responding to this behaviour, the NUSAS general secretary Sheila Lapinsky accused Biko of sexism, to which he responded: "Don't worry about my sexism. What about your white racist friends in NUSAS?" Sobukwe also admonished Biko for his womanising, believing that it set a bad example to other activists. Biko married Ntsiki Mashalaba in December 1970. They had two children together: Nkosinathi, born in 1971, and Samora, born in 1975. Biko's wife chose the name Nkosinathi ("The Lord is with us"), and Biko named their second child after the Mozambican revolutionary leader Samora Machel. Angered by her husband's serial adultery, Mashalaba ultimately moved out of their home, and by the time of his death, she had begun divorce proceedings. Biko had also begun an extra-marital relationship with Mamphela Ramphele. In 1974, they had a daughter, Lerato, who died after two months.
=== Medication === Medications for AS may be broadly considered either "disease-modifying" or "symptom-modifying". Disease-modifying medications for ankylosing spondylitis aim to slow disease progression and include drugs like tumor necrosis factor (TNF) inhibitors. Symptom-modifying medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), primarily address symptoms like pain and inflammation but do not alter the course of the disease.
Sources: en.wikipedia.org
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.
Mass spectrometry establishes the molecular mass, and reversed-phase chromatography reports purity. A certificate of analysis typically combines both results.
Solutions degrade faster than the dry powder, particularly at room temperature. Portioning into single-use aliquots and freezing reduces losses from repeated thawing.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.